TUBERCULOZA: TRECUT ȘI PREZENT
DOI:
https://doi.org/10.52692/1857-0011.2023.3-77.41Cuvinte cheie:
tuberculoză, control, epidemiologie, rezistența bacteriană, evoluție istorică, progrese, strategiiRezumat
Tuberculoza este o boală infecțioasă gravă și răspândită la nivel global, cauzând un număr semnificativ de decese în fiecare an. Aceasta continuă să reprezinte o provocare majoră pentru sistemul de sănătate și necesită eforturi susținute de control și prevenție. Scopul acestei lucrări a fost de a analiza aspectele istorice ale tuberculozei și rezultatele programelor de control la nivel mondial și local. Materialele și metodele utilizate au implicat cercetarea literaturii de specialitate. Principalele concluzii includ evoluția istorică a tuberculozei, impactul descoperirilor și progreselor medicale asupra tratamentului și controlului bolii, precum și necesitatea continuă de a implementa strategii eficiente de prevenție și tratament.
Referințe
Migliori G.B. Tuberculosis: The Essentials. Fourth Edition. European Respiratory Review, 2011; 20 (120) 125.
Paulson T. Epidemiology: A mortal foe. Nature 502, S2–S3 2013.
Huang F., Zhao Y. Global Control of Tuberculosis: Current Status and Future Prospects. Zoonoses. 2022; Vol. 2(1).
Migliori, G. B., & Raviglione, M. C. (Eds.). Essential Tuberculosis. 2021;
Raviglione M. C. Tuberculosis: The Essentials, Fourth Edition (Lung Biology in Health and Disease) 4th Edition. 2009;
World Health Organization. Communicable Diseases Cluster. (1999). What is DOTS? : a guide to understanding the WHO-recommended TB control strategy known as DOTS. World Health Organization. https:// apps.who.int/iris/handle/10665/65979
Stop TB Initiative & Stop TB Partnership. (2002). The global plan to stop tuberculosis : Stop TB Partnership. World Health Organization. https://apps.who.int/iris/ handle/10665/67355
Stop TB Partnership & World Health Organization. (2006). The global plan to stop TB, 2006-2015 / Stop TB Partnership. World Health Organization. https://apps.who.int/iris/handle/10665/43404
Floyd K, Glaziou P, Zumla A, Raviglione M. The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. Lancet Respir Med. 2018 Apr;6(4):299-314.
Bjerrum S., Schiller I., Dendukuri N. et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. Cochrane Database Syst Rev; 2019.
Kraef C, Yedilbayev A, Seguy N, et al. Uptake of the lateral flow urine LAM test in Europe and Central Asia. Int J Tuberc Lung Dis. 2022 Sep 1;26(9):835-841.
Yang C., Sobkowiak B., Naidu V., et al. Phylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis. PLoS Med; 19. 2022.
Vesga J.F., Hallett T.B., Reid M.J.A., et al., Arinaminpathy N. Assessing tuberculosis control priorities in high-burden settings: a modelling approach. Lancet Glob Heal 2019; 7: e585–e595
Afanasiev E.I., Russkikh O.E. Современные тенденции в эпидемиологии туберкулеза и ВИЧ-инфекции в мире и в Российской Федерации. RMJ. 2021;3:24–26.
Barberis I, Bragazzi NL, Galluzzo L., The history of tuberculosis: from the first historical records to the isolation of Koch’s bacillus. J Prev Med Hyg. 2017;58(1):E9-E12.
Barbier M, Wirth T. 2016. The evolutionary history,demography, and spread of the Mycobacterium tuberculosis complex. Microbiol Spectrum 4(4):TBTB2-00082016. doi:10.1128/microbiolspec.TBTB2-0008-2016.
MALIK, Alina. The impact of the molecular genetic test on the diagnosis delay and outcome in patients with pulmonary tuberculosis. In: Moldovan Medical Journal, 2018, nr. 3(61), pp. 3-9.
Chesov D., Crudu V., Soltan V., Botnaru V. Reduction in treatment delay of MDR-TB cases as a result of Xpertt MTB/RIF implementation in Moldova. int j tuberc lung dis 2016; 20: S521.
Syunyakova D.A. особенности эпидемиологии туберкулеза в мире и в россии в период 2015-2020 гг. аналитический ОБЗОР Social’nye aspekty zdorov’a naselenia / Social aspects of population health [serial online] 2021; 67(3):11.
Trajman A, Felker I, Alves LC, et al., The COVID-19 and TB syndemic: the way forward. Int J Tuberc Lung Dis. 2022 Aug 1;26(8):710-719.
Oancea C. et al. Tratat de pneumologie pentru medicii rezidenți, www.umft.ro/editura (2021).
Houben RMGJ, Dodd PJ The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. 2016; PLoSMed13(10):e1002152.
Menzies N., Swartwood N.; Testa C., et al., Time Since Infection and Risks of Future Disease for Individuals with Mycobacterium tuberculosis Infection in the United States. Epidemiology 2021; 32(1):p 70-78.
WHO consolidated guidelines on tuberculosis. Module 4: treatment drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.
European Centre for Disease Prevention and Control, WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2023 – 2021 data. Stockholm: European Centre for Disease Prevention and Control and Copenhagen: WHO Regional Office for Europe. 2023.
Global tuberculosis report 2022. Geneva: World Health organization; 2022. licence: cc bY-Nc-sa 3.0 iGo.
Shariq M, Sheikh JA, Quadir N, et al., COVID-19 and tuberculosis: the double whammy of respiratory pathogens. Eur Respir Rev. 2022 Apr 13;31(164):210264.
Mondoni M, Saderi L, Sotgiu G. Novel treatments in multidrug-resistant tuberculosis. Curr Opin Pharmacol. 2021 Aug;59:103-115.
Shah M, Dorman SE. Latent Tuberculosis Infection. N Engl J Med. 2021 Dec 9;385(24):2271-2280.
Hamada Y, Getahun H, Tadesse BT, et al., HIV-associated tuberculosis. Int J STD AIDS. 2021 Aug;32(9):780-790.
Sultana ZZ, Hoque FU, Beyene J, et al., A. HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2021 Jan 11;21(1):51. doi: 10.1186/s12879-020-05749-2. Erratum in: BMC Infect Dis. 2021 Jan 20;21(1):86.
Descărcări
Publicat
Număr
Secțiune
##category.category##
Licență
Copyright (c) 2024 Buletinul Academiei de Științe a Moldovei. Științe medicale
Această lucrare este licențiată în temeiul Creative Commons Attribution 4.0 International License.